FRANKFURT (Reuters) – Bayer’s CEO said on Friday that the healthcare and crop chemicals group continues to firmly back its glyphosate weedkiller even after a recent courtroom loss in U.S. litigation over an alleged carcinogenic effect.
When asked whether Bayer would alter its legal strategy, CEO Bill Anderson said in a media call that glyphosate is approved and deemed safe by regulators in every major jurisdiction.
“We stand firmly behind the product and that assessment,” said Anderson.
Bayer was last month ordered to pay $2.25 billion to a Pennsylvania man who said he developed cancer from exposure to glyphosate, though the amount of damages is expected to be reduced on appeal.
(Reporting by Ludwig Burger; Editing by Miranda Murray)
Comments